JP2010523081A - Ｃｄｃａ８−ａｕｒｋｂ複合体を標的とするスクリーニング方法およびｎｓｃｌｃの治療方法 - Google Patents

Ｃｄｃａ８−ａｕｒｋｂ複合体を標的とするスクリーニング方法およびｎｓｃｌｃの治療方法 Download PDF

Info

Publication number
JP2010523081A
JP2010523081A JP2010500520A JP2010500520A JP2010523081A JP 2010523081 A JP2010523081 A JP 2010523081A JP 2010500520 A JP2010500520 A JP 2010500520A JP 2010500520 A JP2010500520 A JP 2010500520A JP 2010523081 A JP2010523081 A JP 2010523081A
Authority
JP
Japan
Prior art keywords
seq
cdca8
aurkb
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010500520A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523081A5 (enExample
Inventor
祐輔 中村
弥太郎 醍醐
修一 中鶴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2010523081A publication Critical patent/JP2010523081A/ja
Publication of JP2010523081A5 publication Critical patent/JP2010523081A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
JP2010500520A 2007-03-30 2008-03-27 Ｃｄｃａ８−ａｕｒｋｂ複合体を標的とするスクリーニング方法およびｎｓｃｌｃの治療方法 Withdrawn JP2010523081A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90934707P 2007-03-30 2007-03-30
PCT/JP2008/056657 WO2008120812A1 (en) 2007-03-30 2008-03-27 Screening and therapeutic method for nsclc targeting the cdca8-aurkb complex

Publications (2)

Publication Number Publication Date
JP2010523081A true JP2010523081A (ja) 2010-07-15
JP2010523081A5 JP2010523081A5 (enExample) 2011-05-12

Family

ID=39808392

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010500520A Withdrawn JP2010523081A (ja) 2007-03-30 2008-03-27 Ｃｄｃａ８−ａｕｒｋｂ複合体を標的とするスクリーニング方法およびｎｓｃｌｃの治療方法

Country Status (4)

Country Link
US (1) US20100184047A1 (enExample)
EP (1) EP2142648A4 (enExample)
JP (1) JP2010523081A (enExample)
WO (1) WO2008120812A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012034942A1 (en) 2010-09-13 2012-03-22 Santaris Pharma A/S Compounds for the modulation of aurora kinase b expression
JP5963363B2 (ja) * 2010-09-30 2016-08-03 国立大学法人 鹿児島大学 Ａｕｒｏｒａキナーゼプロモーターを含む増殖制御型ウイルスベクター
WO2012066092A1 (en) 2010-11-19 2012-05-24 Santaris Pharma A/S Compounds for the modulation of aurora kinase a expression
WO2012173846A2 (en) * 2011-06-06 2012-12-20 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN112007161B (zh) * 2020-09-17 2022-10-21 山东大学齐鲁医院 Cdca8在制备治疗卵巢癌药物中的应用
WO2023060211A1 (en) * 2021-10-06 2023-04-13 The University Of Chicago Borealin targeting polypeptides for detection and treatment of cancer
CN119986009A (zh) * 2025-03-03 2025-05-13 西南医科大学附属医院 Aurkb在筛选治疗支气管肺发育不良的药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200533376A (en) * 2004-03-24 2005-10-16 Oncotherapy Science Inc Compositions and methods for treating lung cancer
EP1787122B1 (en) * 2004-08-10 2010-10-06 Oncotherapy Science, Inc. NON-SMALL CELL LUNG CANCER-RELATED GENE, ANLN, AND ITS INTERACTIONS WITH RhoA
JP4908402B2 (ja) * 2004-09-24 2012-04-04 オンコセラピー・サイエンス株式会社 ＵＲＬＣ８のｔＲＮＡ−ジヒドロウリジンシンターゼ活性によって非小細胞肺癌を診断する方法
JP5150855B2 (ja) * 2005-07-29 2013-02-27 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１−ｋｎｔｃ２複合体を標的とするスクリーニングおよびｎｓｃｌｃの治療方法

Also Published As

Publication number Publication date
EP2142648A4 (en) 2011-09-14
US20100184047A1 (en) 2010-07-22
EP2142648A1 (en) 2010-01-13
WO2008120812A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
WO2011096210A1 (en) Prmt1 and prmt6 for target genes of cancer therapy and diagnosis
JP2010536366A (ja) 肺癌の治療及び診断の標的遺伝子のためのｅｂｉ３、ｄｌｘ５、ｎｐｔｘ１、及びｃｄｋｎ３
WO2011096211A1 (en) Whsc1 and whsc1l1 for target genes of cancer therapy and diagnosis
JP5764822B2 (ja) がんの治療および診断の標的遺伝子としてのｐｒｍｔ１
US20110263012A1 (en) Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
JP2010536367A (ja) 癌関連遺伝子、ｃｄｃａ５、ｅｐｈａ７、ｓｔｋ３１及びｗｄｈｄ１
JP5640263B2 (ja) Ｄｅｐｄｃ１ポリペプチドを使用した膀胱癌の治療または予防のための方法
JP2010523081A (ja) Ｃｄｃａ８−ａｕｒｋｂ複合体を標的とするスクリーニング方法およびｎｓｃｌｃの治療方法
WO2010095364A1 (en) Jarid1b for target gene of cancer therapy and diagnosis
EP2785870B1 (en) Smyd2 as a target gene for cancer therapy and diagnosis
JP2012501167A (ja) 膵臓癌関連遺伝子ｔｔｌｌ４
US20120010266A1 (en) Tbc1d7 as tumor marker and therapeutic target for cancer
JP2012501161A (ja) 癌の治療および診断の標的遺伝子としてのｓｙｎｇｒ４
WO2012023290A1 (en) Rasef as tumor marker and therapeutic target for cancer
JP2010501162A (ja) 肺癌の治療標的及び予後指標としてのｉｍｐ−１癌遺伝子
WO2008020653A1 (en) Use of holliday junction-recognizing protein related to cancer
JP2012501166A (ja) 乳癌関連遺伝子ｒｑｃｄ１
WO2012023284A1 (en) Lhx4 as a target gene for cancer therapy and diagnosis
JP2013502901A (ja) がんの治療および診断の標的遺伝子としてのｅｒｃｃ６ｌ
WO2012023288A1 (en) Fam161a as a target gene for cancer therapy and diagnosis
WO2012023259A1 (en) C6orf167 as a target gene for cancer therapy and diagnosis
US20130203625A1 (en) Suv420h1 and suv420h2 as target genes for cancer therapy and diagnosis
CN102575300A (zh) 肺癌治疗和诊断的靶基因cstf2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120309

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120628